Mesto sovremennykh ftorkhinolonov v terapii intraabdominal'nykh infektsiy i infektsiy malogo taza
- 作者: Zuzova AP1
-
隶属关系:
- СГМА, Смоленск
- 期: 卷 11, 编号 2 (2009)
- 页面: 6-9
- 栏目: Articles
- URL: https://ogarev-online.ru/2079-5831/article/view/28008
- ID: 28008
如何引用文章
全文:
详细
参考
- Перитонит. Практическое руководство. Под ред. В.С.Савельева, Б.Р.Гельфанда, М.И.Филимоновой. М., 2006.
- Andersson M.I, Mac Gowan A.P. Development of quinolones. J Antimicrob Chemother 2003; 51 (Suppl. Sl): 1–11.
- Holzheimer R.G, Dralle H. Antibiotic therapy in intra - abdominal infections. A review on randomised clinical trials. Eur J Med Res 2001; 6: 277–91.
- Solomkin J.S, Mazuski J.E, Baron E.J et al. Guidelines for the selection of anti - infective agents for complicated intra - abdominal infections. Clin Infect Dis 2003; 37: 997–1005.
- Takahashi H, Hayakawa I, Akimoto T. The history of the development and changes of guinolone antibacterial agents. Yakushigaku Zasahi 2003; 38 (2): 161–79.
- Hooper D.C. Quinolones. In: Principles and Practice of infections Diseases. Mandel, Douglas, Bennett's. 1999; 451–69.
- Blondean J.M, Missaghi B. Gemifloxacin: a new fluoroquinolone. Expert Opin Pharmacother 2004; 5: 1117–52.
- Keating G.M, Scott L.J. Moxifloxacin. A review of its use in the management of bacterial infections. Drugs 2004; 64 (20): 2347–77.
- Behra-Miellet J, Dubreui A, Jumas-Bilak E. Antianaerobic activity of moxifloxacim campared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta - lactams. Int J Antimicrob Agents 2002; 20 (5): 366–74.
- Kim M.M-R, Nightingale C.H. Pharmacokinetics and pharmacodinamics of the fluoroquinolones. In: The Quinolones. Andriole V.T, ed. San Diego: Academic Press 2000; 169–202.
- Stass H, Rink A.D, Delesen H et al. Pharmacocinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother 2006; 58 (3): 693–6.
- Wacke R, Forster S, Adam U et al. Penetration of moxifloxacin intо the human pancreas following a single intravenous or oral dose. J Antimicrob Chemother 2006; 58 (5): 994–9.
- Яковлев В.П., Яковлев С.В. Возможности профилактического и лечебного применения левофлоксацина. Consilium Medicum 2002; 4.
- Крескен М., Лоде Х. Фторхинолоном какого поколения следует считать левофлоксацин. КМАХ. 2005; 7 (3): 298–305.
- Simpson I, Jones N. Intern J Antimicrob 2001; 17 (Suppl. I): аbstr NP 20.009.
- Hooper D.C. New uses for new and old quinolones and the challenge of resistence. Clin Infect Dis 2000; 30: 243–54.
- Gatifloxacin and moxifloxacin: two new fluoroquinolones. Med Lett Drugs Ther 2000; 42: 15–7.
- Stein E.G, Goldstein E.J. Fluoroquinolones and anaerobes. Clin Infect Dis 2006; 42: 1598–607.
- Malangoni N.M et al. Randomized controlled trial of moxifloxacin compared with piperacillin/tazobactam and amoxicillin/clavulanate for the treatment of complicated intra - abdominal infections. Ann Surg 2006; 244: 204–11.
- Ross J.D.C, Cronje H.S, Rakoczi I et al. Моксифлоксацин в сравнении с комбинацией офлоксацин/метронидазол при НВЗОМТ: результаты КИ. Материалы XVI Международного общества по изучению болезней, передающихся половым путем, ISSTDR. Амстердам. 10–13 июля 2005.
- Heystek M, Tellarini M, Schmitz H et al. Efficacy and safety of moxifloxacin vs ciprofloxacint plus doxycycline plus metronidazole for the treatment of uncomplicated pelvic inflammatory disease (PID). J Antimicrob Chemoter 1999; 44 (Suppl. A): 143.
- Зайцев А.А., Карпов О.И., Стрекачев А.Ю. Новые возможности антибактериальной терапии инфекций в хирургической практике. Антибиот. и химиотер. 2003; 48: 5.
补充文件
